Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD

August 20, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search